Table 1.

Reported cases of concomitant psoriasis and hidradenitis suppurativa.

Authors, reference number and year	Type of study	Patient no./Sex/Age (year)	Clinical course	Diseases severity	Previous treatment for HS	Previous treatments for psoriasis/PsA	Treatment for concomitant psoriasis/PsA and HS	Outcome
Yen et al. (24)	Case series	1/M/66 2/M/57 3/M/46	1/Psoriasis arising before HS 2/Psoriasis and PsA arising before HS 3/Psoriasis and PsA arising before HS	1/PASI 28.9; HS-PGA 4 2/PASI 23.4; HS-PGA 3 3/PASI 11.8; HS-PGA 3	1/Oral cefadroxil, topical gentamicin 2/Oral amoxicillin/clavulanate potassium 3/Oral cefadroxil	1/Acitretin 25 mg/day Methotrexate 7.5 mg/week Cyclosporine 200 mg/day NB-UVB phototherapy 2/Methotrexate 15 mg/week Sulfasalazine 1,000 mg/day Celecoxib 200 mg/day 3/Leflunomide 20 mg/day Acitretin 10 mg/day Cyclosporine 300 mg/day NB-UVB phototherapy	Adalimumab 80 mg on day, followed by 40 mg on day 8, and then every 2 weeks	3 months: 1/PASI 5.6; HS-PGA 0 2/PASI 1; HS-PGA 1 3/PASI 2.2; HS-PGA 1
Giuseppe et al. (23)	Case report	M/37	Psoriasis arising before HS	Both moderate	Oral rifampicin and clindamycin	Cyclosporine Infliximab 5 mg/kg	Secukinumab 300 mg in weeks 0, 1, 2, 3, 4 and then every 4 weeks	1 month: Regression of the abscesses and improvement of psoriatic lesions
Gadelha et al. (22)	Case report	F/22	PsAPASH and psoriasis of the scalp	Hurley stage III, Sartorius score 55	Clindamycin 300 mg every 8 h and metformin 500 mg twice daily	Capillary solution of salicylic acid and betamethasone dipropionate and antisecretory shampoo	Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg every week	2 months: Sartorius score 49
Tampouratzi et al. (21)	Case series	1/F/27 2/M/42	1/Psoriasis and PsA arising before HS 2/Psoriasis and PsA arising before HS	1/PASI 10.5, BSA 10%; Hurley stage II, IHS4 10 2/PASI 18.5, BSA 45%; Hurley stage II, IHS4 10	1/Topical steroids Methotrexate Apremilast 2/ Cyclosporine Methotrexate Golimumab Adalimumab Ustekinumam Secukinumab	1/Topical steroids Methotrexate Apremilast 2/ Cyclosporine Methotrexate Golimumab Adalimumab Ustekinumam Secukinumab	1/Certolizumab pegol 400 mg at week 0 and then every 2 weeks 2/Brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks	3 months: 1/PASI 1, BSA 2%; IHS4 1 4 months: 2/PASI 1.5, BSA 8%; IHS4 3
Proietti et al. (20)	Case report	M/35	Psoriasis, HS, and recent history of SAMPUS	PASI 10.2; Hurley stage III, HS-PGA 3	Antibiotics and retinoids	Not reported	Apremilast 30 mg twice daily	3 months: PASI 2.5, HS-PGA 2
Lanna et al. (19)	Case report	M/55	HS arising before psoriasis	PASI 20, BSA 25%; Hurley stage II	Not reported	Not reported	Apremilast 30 mg twice daily	1 months: PASI 1; Hurley stage 0-I
Navarro-Triviño et al. (18)	Case report	M/58	Secukinumab-induced paradoxical HS arising in a patient with psoriasis and PsA	PASI 0; Hurley stage II	None (HS was a paradoxical reaction to Secukinumab)	Etanercept Adalimumab Secukinumab	Ustekinumab 45 mg	4 months: PASI 0; Hurley stage II
Vellaichamy et a (17).	Case report	F/27	Adalimumab-induced paradoxical HS arising in a patient with psoriasis and vitiligo	PASI 0; Hurley stage II-III	None	Topical treatments Apremilast Adalimumab	Adalimumab dosing increased to weekly and then stopped due to the onset of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)	6 months: PASI 0; Hurley stage II-III
Yoshida et al. (16)	Case report	M/47	Psoriasis and HS	PASI 10.8; Hurley stage III, modified Sartorius score 102	Antibiotics and stab incision drainage	Topical steroids	Brodalumab 210 mg weekly for 2 weeks and then every 2 weeks	8 months: PASI 0; Hurley stage II, modified Sartorius score 30
Licata et al. (15)	Case report	M/50	Psoriasis arising before HS	PASI 25, BSA 20%; Hurley stage II	Cyclosporine 4 mg/kg/day Metotrexate 20 mg/week Adalimumab 40 mg/week	Cyclosporine 4 mg/kg/day Metotrexate 20 mg/week Adalimumab 40 mg/week	Risankizumab 150 mg at weeks 0, 4, and every 12 weeks thereafter	4 months: PASI 0, BSA 0; Hurley stage 0
Garcovich et al. (14)	Case series	1/M/73 2/M/51	1/Psoriasis, PsA and HS 2/Psoriasis, PsA and HS	1/PASI 5; DAPSA 55; Hurley stage III, HS-PGA 4 2/DAPSA 48.2; Hurley stage III, HS-PGA 5	1/Tetracyclines, rifampicin, and clyndamicin 2/Carbapenems, Cotrimaxozole Beta-lactams Cyclosporine Steroids Methotrexate Retinoids Infliximab Etanercept Adalimumab Secukinumab	1/Systemic steroids and NSAIDs 2/Carbapenems, cotrimaxozole, beta-lactams Cyclosporine Steroids Methotrexate Retinoids Infliximab Etanercept Adalimumab Secukinumab	1/Apremilast 30 mg twice daily 2/Apremilast 30 mg twice daily	4 months: 1/DAPSA 12.8; HS-PGA 2 2/DAPSA 16.7; HS-PGA 3
Gkini and Bewley (13)	Case report	F/19	Ustekinumab-induced paradoxical HS arising in a patient with psoriasis	PASI 13, Hurley stage III	Flucloxacillin, minocycline 100 mg/day, incisional drainage	Topical and conventional systemic drugs Ustekinumab 45 mg/3 months	Adalimumab 40 mg/week and surgery	6 months: Improvement (PASI and Hurley stage not reported)
Odorici et al. (12)	Case report	M/46	Secukinumab-induced paradoxical HS arising in a patient with psoriasis and PsA	PASI 12; Sartorius score 54	None (HS was a paradoxical reaction to Secukinumab)	Infliximab Etanercept. Adalimumab Secukinumab 300 mg/4 weeks	Ixekizumab 160 mg at week 0, 80 mg every other week for 12 weeks, and then 80 mg every 4 weeks	5 months: PASI: 2.2; Sartorius score 16
Musumeci et al. (11)	Case series	1/F/32 2/F/32	1/2/Adalimumab-induced paradoxical psoriasis arising in a patient with HS	1/PASI 5; Hurley stage III 2/PASI 7; Hurley stage II	1/2/Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg every week	1/2/None (Psoriasis was a paradoxical reaction to Adalimumab)	1/2Adalimumab discontinuation followed by treatment with topical steroids	3 months: 1/2/Improvement of psoriasis and no HS worsening (PASI and Hurley stage not reported)